Stem Cell Treatment in Retinal Diseases: Recent Developments

Ayşe ÖNER (Erciyes University Faculty of Medicine, Department of Ophthalmology, Kayseri, Turkey)
Türk Oftalmoloji Dergisi
4 2
Yıl: 2018 Cilt: 48 Sayı: 1 Sayfa Aralığı: 33 - 38 Metin Dili: İngilizce DOI: 10.4274/tjo.89972 İndeks Tarihi: 11-12-2018

Stem Cell Treatment in Retinal Diseases: Recent Developments

Öz:
Stem cells are undifferentiated cells which have the ability to self-renew and differentiate into mature cells. They are highly proliferative,implying that an unlimited number of mature cells can be generated from a given stem cell source. On this basis, stem cell replacementtherapy has been evaluated in recent years as an alternative for various pathologies. Degenerative retinal diseases cause progressive visualdecline which originates from continuing loss of photoreceptor cells and outer nuclear layers. Theoretically, this therapy will enablethe generation of new retinal cells from stem cells to replace the damaged cells in the diseased retina. In addition, stem cells are able toperform multiple functions, such as immunoregulation, anti-apoptosis of neurons, and neurotrophin secretion. With recent progress inexperimental stem cell applications, phase I/II clinical trials have been approved. These latest stem cell transplantation studies showedthat this therapy is a promising approach to restore visual function in eyes with degenerative retinal diseases such as retinitis pigmentosa,Stargardts’ macular dystrophy, and age-related macular degeneration. This review focuses on new developments in stem cell therapy fordegenerative retinal diseases.
Anahtar Kelime:

Konular: Göz Hastalıkları
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Limoli PG, Limoli C, Vingolo EM, Scalinci SZ, Nebbioso M. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016;7:46913-46923.
  • Satarian L, Nourinia R, Safi S, Kanavi MR, Jarughi N, Daftarian N, Arab L, Aghdami N, Ahmadieh H, Baharvand H. Intravitreal Injection of Bone Marrow Mesenchymal Stem Cells in Patients with Advanced Retinitis Pigmentosa; a Safety Study. J Ophthalmic Vis Res. 2017;12:58-64.
  • Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, Pandya HK, Leonard RE 2nd, Parrot MB, Rosenfeld PJ, Flynn HW Jr, Goldberg JL. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N Engl J Med. 2017;376:1047-1053.
  • Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissuederived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther. 2016;7:178.
  • Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014;56:81-89.
  • Siqueira RC, Messias A, Messias K, Arcieri RS, Ruiz MA, Souza NF, Martins LC, Jorge R. Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial) Stem Cell Res Ther. 2015; 6:29.
  • . Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina. 2011;31:1207-1214.
  • Haddad-Mashadrizeh A, Bahrami AR, Matin MM, Edalatmanesh MA, Zomorodipour A, Gardaneh M, Farshchian M, Momeni-Moghaddam M. Human adipose-derived mesenchymal stem cells can survive and integrate into the adult rat eye following xenotransplantation. Xenotransplantation. 2013;20:165-176.
  • Castanheira P, Torquetti L, Nehemy MB, Goes AM. Retinal incorporation and differentiation of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq Bras Oftalmol. 2008;71:644-650.
  • Huang C, Zhang J, Ao M, Li Y, Zhang C, Xu Y, Li X, Wang W. Combination of retinal pigment epithelium cell-conditioned medium and photoreceptor outer segments stimulate mesenchymal stem cell differentiation toward a functional retinal pigment epithelium cell phenotype. J Cell Biochem. 2012;113:590-598.
  • Tsuruma K, Yamauchi M, Sugitani S, Otsuka T, Ohno Y, Nagahara Y, Ikegame Y, Shimazawa M, Yoshimura S, Iwama T, Hara H. Progranulin, a major secreted protein of mouse adipose-derived stem cells, inhibits lightinduced retinal degeneration. Stem Cells Transl Med. 2014;3:42-53.
  • Jian Q, Li Y, Yin ZQ. Rat BMSCs initiate retinal endogenous repair through NGF/TrkA signaling. Exp Eye Res. 2015;132:34-47.
  • Guan Y, Cui L, Qu Z, Lu L, Wang F, Wu Y, Zhang J, Gao F, Tian H, Xu L, Xu G, Li W, Jin Y, Xu GT. Subretinal transplantation of rat MSCs and erythropoietin gene modified rat MSCs for protecting and rescuing degenerative retina in rats. Curr Mol Med. 2013;13:1419-1431.
  • Sugitani S, Tsuruma K, Ohno Y, Kuse Y, Yamauchi M, Egashira Y, Yoshimura S, Shimazawa M, Iwama T, Hara H. The potential neuroprotective effect of human adipose stem cells conditioned medium against light-induced retinal damage. Exp Eye Res. 2013;116:254-264.
  • Chen PM, Yen ML, Liu KJ, Sytwu HK, Yen BL. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci. 2011;18:49.
  • Emre E, Yüksel N, Duruksu G, Pirhan D, Subaşi C, Erman G, Karaöz E. Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow-derived mesenchymal stem cells in an experimental ocular hypertension model. Cytotherapy. 2015;17:543-559.
  • Konno M, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, Nishikawa S, Ohta K, Kano Y, Ozaki M, Noguchi Y, Sakai D, Kudoh T, Kawamoto K, Eguchi H, Satoh T, Tanemura M, Nagano H, Doki Y, Mori M, Ishii H. Adipose-derived mesenchymal stem cells and regenerative medicine. Dev Growth Differ. 2013;55:309-318.
  • Huo DM, Dong FT, Yu WH, Gao F. Differentiation of mesenchymal stem cell in the microenviroment of retinitis pigmentosa. Int J Ophthalmol. 2010;3:216-219.
  • Harasymiak-Krzy anowska I, Niedojad o A, Karwat J, Kotu a L, GilKulik P, Sawiuk M, Kocki J. Adipose tissue-derived stem cells show considerable promise for regenerative medicine applications. Cell Mol Biol Lett. 2013;18:479-493.
  • Bharti K, Rao M, Hull SC, Stroncek D, Brooks BP, Feigal E, van Meurs JC, Huang CA, Miller SS. Developing cellular therapies for retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2014;55:1191-1202.
  • He Y, Zhang Y, Liu X, Ghazaryan E, Li Y, Xie J, Su G. Recent Advances of Stem Cell Therapy for Retinitis Pigmentosa. Int J Mol Sci. 2014;15:14456- 14474.
  • Pera MF. Stem cells: The dark side of induced pluripotency. Nature. 2011;471:46-47.
  • Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol. 2015;33:890-891.
  • Li Y, Tsai YT, Hsu CW, Erol D, Yang J, Wu WH, Davis RJ, Egli D, Tsang SH. Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med 2012;18:1312-1319.
  • Tucker BA, Park IH, Qi SD, Klassen HJ, Jiang C, Yao J. Redenti S, Daley GQ, Young MJ. Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One 2011;6:18992.
  • Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado A, Semo M, Smart MJ, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey PJ. Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One. 2009;4:8152.
  • Zhao T, Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol. 2010;20:170-175.
  • Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, AntosiewiczBourget J, O’Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011;471:68-73.
  • Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature. 2010;465:175-181.
  • Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, Aimiuwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, Lavon N, Benvenisty N, Croce CM, Clark AT, Baxter T, Pyle AD, Teitell MA, Pelegrini M, Plath K, Lowry WE.Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5:111-123.
  • Zhao T. Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;13:474:212-215.
  • Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081-3089.
  • Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
  • Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
  • Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal Transplantation of Embryonic Stem Cell-Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An Assessment at 4 Years. Invest Ophthalmol Vis Sci. 2016;57:ORSFc1-9.
  • Song WK, Park KM, Kim HJ, Lee JH, Choi J, Chong SY, Shim SH, Del Priore LV, Lanza R. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports. 2015;4:860-872.
  • Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509-516.
  • Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713-20.
  • . Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R, Lund R. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27:2126-2135.
  • Vugler A, Carr AJ, Lawrence J, Chen LL, Burrell K, Wright A, Lundh P, Semo M, Ahmado A, Gias C, da Cruz L, Moore H, Andrews P, Walsh J, Coffey P. Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation. Exp Neurol. 2008;214:347-361.
  • Lund RD, Wang S, Klimanskaya I, Holmes T, Ramos-Kelsey R, Lu B, Girman S, Bischoff N, Sauve Y, Lanza R. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006;8:189-199.
  • Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, YachimovichCohen N, Khaner H, Smith Y, Wiser O, Gropp M, Cohen MA, Even-Ram S, Berman-Zaken Y, Matzrafi L, Rechavi G, Banin E, Reubinoff B. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell. 2009;5:396-408.
  • Banin E, Obolensky A, Idelson M, Hemo I, Reinhardtz E, Pikarsky E, Ben-Hur T, Reubinoff B. Retinal incorporation and differentiation of neural precursors derived from human embryonic stem cells. Stem Cells. 2006;24:246-257.
  • Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells. 2006;24:274-283.
  • Meyer JS, Katz ML, Maruniak JA, Kirk MD. Neural differentiation of mouse embryonic stem cells in vitro and after transplantation into eyes of mutant mice with rapid retinal degeneration. Brain Res. 2004;1014:131-144.
  • Whiting P, Kerby J, Coffey P, da Cruz L, McKernan R. Progressing a human embryonic stem-cell-based regenerative medicine therapy towards the clinic. Philos Trans R Soc Lond B Biol Sci. 2015;370:20140375.
  • Tucker BA, Mullins RF, Stone EM. Stem cells for investigation and treatment of inherited retinal disease. Human Mol Genet. 2014;23:9-16.
  • Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
  • Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, Lu SJ, Zdravkovic T, Ilic D, Genbacev O, Fisher S, Krtolica A, Lanza R. Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell. 2008;2:113-117.
  • Uy HS, Chan PS, Cruz FM. Stem Cell Therapy: a Novel Approach for Vision Restoration in Retinitis Pigmentosa. Med Hypothesis Discov Innov Ophthalmol. 2013;2:52-55.
  • Bennicelli JL, Bennett J. Stem cells set their sights on retinitis pigmentosa. ELife. 2013;2:e01291.
  • Shintani K, Shechtman DL, Gurwood AS. Review and update: Current treatment trends for patients with retinitis pigmentosa. Optometry. 2009;80:384-401.
  • Siqueira RC. Stem cell therapy for retinal diseases: update. Stem Cell Res Ther. 2011;2:50.
  • Zarbin M. Cell-Based Therapy for Degenerative Retinal Disease. Trends Mol Med. 2016;22:115-134.
APA ÖNER A (2018). Stem Cell Treatment in Retinal Diseases: Recent Developments. , 33 - 38. 10.4274/tjo.89972
Chicago ÖNER Ayse Stem Cell Treatment in Retinal Diseases: Recent Developments. (2018): 33 - 38. 10.4274/tjo.89972
MLA ÖNER Ayse Stem Cell Treatment in Retinal Diseases: Recent Developments. , 2018, ss.33 - 38. 10.4274/tjo.89972
AMA ÖNER A Stem Cell Treatment in Retinal Diseases: Recent Developments. . 2018; 33 - 38. 10.4274/tjo.89972
Vancouver ÖNER A Stem Cell Treatment in Retinal Diseases: Recent Developments. . 2018; 33 - 38. 10.4274/tjo.89972
IEEE ÖNER A "Stem Cell Treatment in Retinal Diseases: Recent Developments." , ss.33 - 38, 2018. 10.4274/tjo.89972
ISNAD ÖNER, Ayse. "Stem Cell Treatment in Retinal Diseases: Recent Developments". (2018), 33-38. https://doi.org/10.4274/tjo.89972
APA ÖNER A (2018). Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi, 48(1), 33 - 38. 10.4274/tjo.89972
Chicago ÖNER Ayse Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi 48, no.1 (2018): 33 - 38. 10.4274/tjo.89972
MLA ÖNER Ayse Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi, vol.48, no.1, 2018, ss.33 - 38. 10.4274/tjo.89972
AMA ÖNER A Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi. 2018; 48(1): 33 - 38. 10.4274/tjo.89972
Vancouver ÖNER A Stem Cell Treatment in Retinal Diseases: Recent Developments. Türk Oftalmoloji Dergisi. 2018; 48(1): 33 - 38. 10.4274/tjo.89972
IEEE ÖNER A "Stem Cell Treatment in Retinal Diseases: Recent Developments." Türk Oftalmoloji Dergisi, 48, ss.33 - 38, 2018. 10.4274/tjo.89972
ISNAD ÖNER, Ayse. "Stem Cell Treatment in Retinal Diseases: Recent Developments". Türk Oftalmoloji Dergisi 48/1 (2018), 33-38. https://doi.org/10.4274/tjo.89972
Sayfa Oluşturulma Tarihi
25-04-2024 2:38

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları